FIG. 3.

Sensitivity of early and late X4 HIV-1 variants from the five patients to CXCR4 antagonists. (A) Sensitivities of early and late virus variants to AMD3100 in pooled PHA-PBMC from eight different healthy blood donors. (B) Sensitivities of early and late virus variants to T22 in pooled PHA-PBMC from eight different healthy blood donors. Average values and standard errors of three to six virus variants obtained early after the emergence of X4 HIV-1 variants in vivo (open circles) and of four or five variants obtained 2 to 3 years thereafter (filled circles) are indicated. Percent inhibition relative to control infections was calculated. A negative value represents an increase in viral replication compared to the control infections. Experiments were performed in triplicate, and a representative graph of at least two independent experiments is shown.